Tasimelteon (HETLIOZ®) effective in the treatment of Jet Lag Disorder in an 8-hour phase advance; a multicenter, randomized, double-blind, placebo-controlled trial

Christos M Polymeropoulos, Michael A Mohrman, Madison S Keefe, Jennifer L Brzezynski, Jingyuan Wang, Lydia S Prokosch, Vasilios M Polymeropoulos, Changfu Xiao, Gunther Birznieks, Mihael H Polymeropoulos
doi: https://doi.org/10.1101/2020.04.07.20053306

Article Information

doi 
https://doi.org/10.1101/2020.04.07.20053306
History 
  • April 10, 2020.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Christos M Polymeropoulos, MD1,*,
  2. Michael A Mohrman1,
  3. Madison S Keefe1,
  4. Jennifer L Brzezynski1,
  5. Jingyuan Wang, PhD1,
  6. Lydia S Prokosch1,
  7. Vasilios M Polymeropoulos, MD1,
  8. Changfu Xiao, PhD1,
  9. Gunther Birznieks1 and
  10. Mihael H Polymeropoulos, MD1
  1. 1Vanda Pharmaceuticals Inc.
  1. ↵*Corresponding author; email: christos.polymeropoulos{at}vandapharma.com
Back to top
Posted April 10, 2020.
Download PDF
Data/Code
Email
Tasimelteon (HETLIOZ®) effective in the treatment of Jet Lag Disorder in an 8-hour phase advance; a multicenter, randomized, double-blind, placebo-controlled trial
Christos M Polymeropoulos, Michael A Mohrman, Madison S Keefe, Jennifer L Brzezynski, Jingyuan Wang, Lydia S Prokosch, Vasilios M Polymeropoulos, Changfu Xiao, Gunther Birznieks, Mihael H Polymeropoulos
medRxiv 2020.04.07.20053306; doi: https://doi.org/10.1101/2020.04.07.20053306
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area